Abstract:DprE1 enzyme has emerged as one of the most vulnerable targets in M. tuberculosis and non‐covalent DprE1 inhibitors attracted considerable attention for the discovery of new anti‐tubercular agents. Among these compounds, TCA1, a non‐covalent DprE1 inhibitor has emerged as a potent drug candidate. In this regard, a series of TCA1 analogs were prepared through the pharmacophore hopping and evaluated for their anti‐tubercular activity against H37Ra. Among the compounds, Compounds 6 b and 6 f were emerged as lead compounds with MICs values of 4.0 and 8μg/mL respectively. Inhibitors of Decaprenylphosphoryl‐β‐D‐ribose 2′‐epimerase (DprE1) are being thoroughly explored as potential pharmacological entities for the development of new anti‐tubercular therapeutics. In this context, benzothiazole‐bearing compounds have emerged as potential non‐covalent DprE1 inhibitors active against mycobacterium tuberculosis. In view of the promising anti‐tubercular activity of benzothiazole based non‐covalent DprE1 inhibitor TCA1; a series of thirty small peptide conjugates of benzothiazole‐2‐carboxylic acid has been synthesized and evaluated for their anti‐tubercular activity against the M.tb H37Ra strain by broth microdilution assay. Among the compounds tested, compounds methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate and methyl (6‐methylbenzo[d]thiazole‐2‐carbonyl)tryptophylalaninate demonstrated potential anti‐tubercular activity with minimum inhibitory concentration (MIC) values of 4 and 8 μg/mL, respectively. These compounds were further identified to be mycobactericidal and are completely killing the microbes at 8‐16 μg/mL concentrations. Furthermore, the cytotoxicity study of most potent compound methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate illustrated no significant toxicity to the human cell line HepG2. Moreover, synthesised compounds were subject to molecular docking, ADME studies and MM‐GBSA calculations. In silico studies suggest that these compounds show strong interactions with key amino acids in the binding pocket of DprE1 (PDBID: 4KW5) with the most active conjugates residing well (with docking scores of −08.49 and −7.902 kcal/mol).

DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery

Novel hybrids of 1,2,3-triazole-benzoxazole: design, synthesis, and assessment of DprE1 enzyme inhibitors using fluorometric assay and computational analysis

3D-QSAR and ADMET studies of morpholino-pyrimidine inhibitors of DprE1 from Mycobacterium tuberculosis

Design, Synthesis and Evaluation of Covalent Inhibitors of DprE1 As Antitubercular Agents.

Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment

Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents

Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening

Small Peptide Conjugates of Benzothiazole‐2‐Carboxylic Acids Targeting DprE1 Against Tuberculosis

Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1)

Recent Advancements in Benzothiazinones (BTZ) Analogs as DprE1 Inhibitor for Potent Antitubercular Therapeutics

Recent advances in the development of DprE1 inhibitors using AI/CADD approaches

Structure and inhibition mechanisms of Mycobacterium tuberculosis essential transporter efflux protein A

Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains

DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs

Discovery of N -(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis

Pharmacophore mapping, 3D QSAR, molecular docking, and ADME prediction studies of novel Benzothiazinone derivatives

Identification of novel inhibitors for Prp protein of Mycobacterium tuberculosis by structure based drug design, and molecular dynamics simulations

Structure based virtual screening and discovery of novel inhibitors against FabD protein of Mycobacterium tuberculosis

The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective

Exploration of potential inhibitors for tuberculosis via structure‐based drug design, molecular docking, and molecular dynamics simulation studies

Structure and inhibition mechanisms of essential transporter efflux protein A